U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H26N6O10S2
Molecular Weight 670.67
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFPIMIZOLE

SMILES

[H][C@]12SCC(C[N+]3=CC=C(CCS([O-])(=O)=O)C=C3)=C(N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)C4=C(N=CN4)C(O)=O)C5=CC=CC=C5)C(O)=O

InChI

InChIKey=LNZMRLHZGOBKAN-KAWPREARSA-N
InChI=1S/C28H26N6O10S2/c35-23(18(16-4-2-1-3-5-16)31-24(36)19-20(27(38)39)30-14-29-19)32-21-25(37)34-22(28(40)41)17(13-45-26(21)34)12-33-9-6-15(7-10-33)8-11-46(42,43)44/h1-7,9-10,14,18,21,26H,8,11-13H2,(H5-,29,30,31,32,35,36,38,39,40,41,42,43,44)/t18-,21-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C28H26N6O10S2
Molecular Weight 670.67
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Cefpimizole is an antibiotic of broad spectrum developed in Japan for the treatment of such conditions as uncomplicated gonorrhea and gynecologic infections. The drug was tested in clinical trials, however, its development was terminated.

Originator

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown
Curative
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
1.0 g of cefpimizole (gonorrea treatment).
Route of Administration: Intramuscular
In Vitro Use Guide
In vitro activity of cefpimizole was tested against C. diversus (MIC 0.4-12.5 ug/ml), H. influenzae (MIC 0.1-0.4 ug/ml), N. gonorrhoeae (MIC 0.1-1.6 ug/ml), Proteus mirabilis (MIC 0.2-12.5 ug/ml), Streptococcus pyogenes (MIC 0.4-3.1 ug/ml), Streptococcus bovis (MIC 1.6-3.1 ug/ml), Streptococcus mitis (MIC 0.2-3.1 ug/ml), Streptococcus agalactiae (MIC 0.8-3.1 ug/ml).
Substance Class Chemical
Record UNII
24S58UHU7N
Record Status Validated (UNII)
Record Version